Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04260217 · ClinicalTrials.gov registry record · Phase 1
APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia
A Phase 1 study, sponsored by Ascentage Pharma Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT04260217 is a Phase 1 study that has completed, run by Ascentage Pharma Group. The registered enrollment target is 46 participants.
The verdict
NCT04260217, a Phase 1 study, has completed, sponsored by Ascentage Pharma Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
Phase Ib/II study of safety, tolerability, efficacy and PK of APG-2575 as a single agent or in combination with other therapeutic agents including ibrutinib or rituximab.
Interventions
- DRUG APG2575 400 mg
- DRUG APG2575 600 mg
- DRUG APG2575 800 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-05-30 |
| Est. Completion | 2025-08-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04260217
The ClinicalTrials.gov registry entry for NCT04260217 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascentage Pharma Group, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which APG2575 400 mg is the first listed.
NCT04260217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04260217 about?
NCT04260217 is a clinical study titled "APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia". Phase Ib/II study of safety, tolerability, efficacy and PK of APG-2575 as a single agent or in combination with other therapeutic agents including ibrutinib or rituximab.
What is the current status of trial NCT04260217?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2021-05-30. Estimated completion is 2025-08-13.
What interventions are being tested in trial NCT04260217?
The interventions under investigation include: APG2575 400 mg (DRUG), APG2575 600 mg (DRUG), APG2575 800 mg (DRUG).
Who is sponsoring clinical trial NCT04260217?
This trial is sponsored by Ascentage Pharma Group, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.